Gene therapy needs to become a commodity and we'd rather do it now so we don't wait for five years because we know there's competitors out there, there's the US and there's Europe. They're thinking about this now.
I work for MeiraGTX. We have a portfolio that is specialising in inherited retinal disease and also neuro-degenerative diseases.
Currently when you manufacture gene therapy products you would use a bacterially derived plasmid, this takes time, it's labour intensive and it introduces impurities into the process. Using a fully synthetic process, there's far fewer impurities and it's available in a higher quantity in a shorter time.
Virus manufacturing is made in clean rooms as the one behind me and in order to make it cheaply and available for a larger amount of people we need to make production runs in bioreactors and then instead of being able to help a hundred or so patients we can help a few thousand patients.
What synthetic does or this project does for us, it takes out that biological variability. So really this technology allows us to pick up what we have and deploy it elsewhere.
This will result in us being able to address markets that we wouldn't have been able to address previously.
The ISCF Medicines manufacturing challenge, it's really set up there to actually take something that's really innovative and commercialise it. So by winning this grant and allowing us to actually engage with companies that are in this field, this synthetic DNA field, we fast track that ability to go to second generation.
Find out more about the Industrial Strategy Challenge Fund investment for Medicines manufacturing here: https://innovateuk.blog.gov.uk/tag/me...
Subscribe to our YouTube channel here: https://www.youtube.com/user/Innovate...
ISCF Winners - Medicines Manufacturing - MeiraGTx funding societies | |
| 9 Likes | 9 Dislikes |
| 976 views views | 6.68K followers |
| Science & Technology | Upload TimePublished on 8 Feb 2018 |
Không có nhận xét nào:
Đăng nhận xét